Genetic variations at the CCAAT/enhancer-binding protein are associated with metabolic phenotypes in the Japanese population

Metabolic Syndrome and Related Disorders

Volumn 6, Issue 1, 2008, Pages 24-31

  Kaji, Hidesuke ^a,b   Fukano, Chika ^a   Kimura, Yukari ^a   Takiguchi, Etsuko ^a   Tanida, Keiko ^a  

^a UNIVERSITY OF HYOGO   (Japan)

^b University of Hyogo   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; OBESITY; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; DNA MUTATIONAL ANALYSIS; FASTING; FEMALE; GENETIC SCREENING; HUMANS; HYPERTENSION; JAPAN; MALE; METABOLIC DISEASES; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 40549105064     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2007.0022     Document Type: Article

References (28)

1. Björntorp P. Metabolic implication of body fat distribution. Diabetes Care 1991;14:1132-1143.
2. Fryan KN. Visceral fat and insulin resistance: causative or correlative? Br J Nutr 2000;83(suppl. 1):71-77.
3. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endcr Rev 2000;21:697-738.
4. Matuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X:contributors of adipocytokine, adipocyte-derived bioactive substances. Ann NY Acad Sci 1999;892:146-154.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
6. Examination Committee of Criteria for the Metabolic Syndrome in Japan. Definition and diagnosis criteria of metabolic syndrome. J Jpn Soc Intern Med (in Japanese) 2005;94:794-809.
7. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new world-wide definition. Lancet 2005;366:1059-1062.
8. Kahn R, Ferrannini E, Buse J, Stern M. The metabolic syndrome: Time for a critical appraisal. Diabetes Care2005;28:2289-2304.
9. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L, Blangero J, Comuzzie AG. Quantitative trait loci on chromosome 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 2000;97:14478-14483.
10. McCarthy JJ, Meyer J, Moliterno DJ, Newby LK, Rogers WJ, Topol EJ. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet 2003;114:87-98.
11. Lopes C, Diana C, Durand E, Froguel P. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologica 2003;46:1284-1290.
12. Shin HD, Park BL, Kim LH, Jung HS, Cho YM, Moon MK, Park YJ, Lee HK, Park KS. Genetic polymorphisms in peroxisome proliferator-activated receptor associated with obesity. Diabetes 2004;53:847-851.
13. Weng SW, Liou CW, Lin TK, Wei YH, Lee CF, Eng HOL, Chen SD, Liu RT, Chen JF, Chen IY, Chen MF, Wang PW. Association of mitochondrial deoxyribonucleic acid 16189 variant (T→C transition) with metabolic syndrome in Chinese adults. J Clin Endocrinol Metab 2005;90:5037-5040.
14. Sutton BS, Weinert S, Langefeld CD, Williams AH, Campbell JK, Saad MF, Haffner SM, Norris JM, Bowden DW. Genetic analysis of adiponectin and obesity in Hispanic families:the IRAS family study. Hum Genet 2005;117:107-118.
15. Baessler A, Hasinoff MJ, Fisher M, Reinhard W, Sonnenberg GE, Olivier M, Erdmann J, Schunkert H, Doering A, Jacob HJ, Comuzzie AG, Kissebah AH, Kwitek AE. Genetic linkage and association of the growth hormone secretagogue receptor (ghrelin receptor) gene in human obesity. Diabetes 2005;54:259-267.
16. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294;2166-2170.
17. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004;53:931-938.
18. Burton GR, Guan Y, Nagarajan R, McGehee RE Jr. Microarray analysis of gene expression during early adipocyte differentiation. Gene 2002;293:21-31.
19. Tanaka T, Yoshida N, Kishimoto T, Akira S. Defective adipocyte differentiation in mice lacking the C/EBP β and/or C/EBP δ gene. EMBO J 1997;24:7432-7443.
20. Takahashi Y, Kaji H, Okimura Y, Goji K, Abe H, Chihara K. Short stature caused by a mutant growth hormone New Engl J Med 1996;334:432-436.
21. Kaji H, Nose O, Tajiri H, Takahashi Y, Iida K, Takahashi T, Okimura Y, Abe H, Chihara K. Novel compound heterozygous mutations of growth hormone (GH) receptor in a patient with GH insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3705-3709.
22. The Examination Committee of Criteria for "Obesity Disease" in Japan, Japan Society for Study of Obesity. New criteria for 'Obesity disease' in Japan. Circ J 2002;66:987-992
23. Miyawaki T, Hirata M, Moriyama K, Sasaki Y, Aono H, Sato N, Nakao K. Metabolic syndrome in Japanese diagnosed with visceral fat measurement by computed tomography. Proc Japan Acad 2005;81:471-479.
24. Hara K, Yokoyama T, Matsushita Y, Tanaka H, Horikoshi M, Kadowaki T, Yoshiike N. A proposal for the cutoff point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population. Diabetes Care 2006;29:1123-1124.
25. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27:S15-S35
26. Changhua JI, Chang E, Centrella M, McCarthy TL. Activation domains of CCAAT enhancer binding protein δ: regions required for native activity and prostaglandin E2-dependent transactivation of insulin-like growth factor I gene expression in rat osteoblasts. Mol Endocrinol 2003;17:1834-1843.
27. Kim J, Cantwell CA, Johnson PF, Pfarr CM, Williams SC. Transcriptional activity of CCAAT/enhancer-binding protein is controlled by a conserved inhibitory domain that is a target for sumoylation. J Biol Chem 2002;41:38037-38044.
28. Vegesna V, Takeuchi S, Hofmann WK, Ikezoe T, Tavor S, Krug U, Fermin AC, Heaney A, Miller CW, Koeffler HP. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res 2002; 26:451-457.